Cystic Fibrosis Market Size ,Share | Growth Forecast Report 2030
Cystic Fibrosis Market Share, Size, Trends, Industry Analysis Report, 2022 - 2030

Cystic Fibrosis Market Share, Size, Trends, Industry Analysis Report, By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements), Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030

  • Published Date:Aug-2022
  • Pages: 118
  • Format: PDF
  • Report ID: PM1325
  • Base Year: 2021
  • Historical Data: 2018-2020

Report Outlook

Cystic fibrosis market size was valued at USD 5.75 billion in 2021 and is expected to grow at a CAGR of 24.3 % during the forecast period. Increasing awareness about this progressive genetic disease and the growing adoption of drug therapies are some of the prominent factors driving the cystic fibrosis market growth. The widespread availability of different treatment options will expand the industry size over the coming years.

The research report offers a quantitative and qualitative analysis of the Cystic Fibrosis Market to enable effective decision-making. It covers the key trends and growth opportunities anticipated to have a favorable impact on the market. Besides, the study covers segment and regional revenue forecasts for market assessment.

Cystic Fibrosis Market Size
Know more about this report: Request for sample pages

It is a chronic disease that affects the digestive system, lungs, and other body organs significantly. The most common symptoms of patients suffering from the disease include difficulty in breathing, lung infections such as pneumonia or bronchitis, weight gain, and bowel movement problems, among others.

According to Cystic Fibrosis Patient Registry, more than 30,000 people are currently suffering from this condition in the U.S., while more than 70,000 people are suffering from it across the globe. In addition to this, more than approximately 1000 new cases of the disease are diagnosed every year. The growing incidence of this disease is likely to spur demand for combination treatments that will foster the industry progression over thin the future years.

The new entrant in the industry, such as carbon sciences, was able to raise USD 38 million in funding for the development of alternative treatment approaches like gene therapy. The firm plans to innovate and develop more unconventional gene therapy solutions for these patients.

Stringent regulations delay approval of drugs, higher cost of therapy, and several adverse effects of currently available drugs such as liver problems, upper respiratory tract infection, chest pain, and increased blood pressure, among others, will hinder the industry growth.

Nationwide lockdowns on account of Covid-19 have led to cancellations of medical appointments and scheduled surgeries at hospitals. This had muted the industry growth for some time; however, the rising number of cases of respiratory illness post-Covid-19 pandemic has spurred the cystic fibrosis industry growth. It has given the key industry players an opportunity to focus on the development of new drugs that can enable fast recovery and reduce mortality rates across the globe.

Cystic Fibrosis Market
Know more about this report: Request for sample pages

Industry Dynamics

Growth Drivers
Increasing spending on R&D research in the industry, coupled with other technological advancements in this therapeutic area, will open new avenues of growth for industry participants. Researchers at NIH developed a wearable sensor that helps in the diagnosis and monitoring of disease progression. The sensor detects the improper salt balance in the body of patients and transmits the data wirelessly for analysis.

A variety of oral and inhaled drugs are available for the treatment that increases compliance to the treatment owing to the ease and convenience of administering it. Rising innovation in the development of new therapies and drug products to cure the disease is anticipated to expand the cystic fibrosis market over the analysis period.

Report Segmentation

The market is primarily segmented based on drug class, route of administration, distribution channel, and region.


By Drug Class


By Route of Administration


By Distribution channel

By Region

  • CFTR modulators
  • Mucolytics
  • Bronchodilators
  • Pancreatic enzyme supplements
  • Others


  • Oral drugs
  • Parenteral drugs


  • Hospital
  • Retail pharmacies
  • Others


  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report: Request for sample pages

Cystic fibrosis transmembrane conductance regulator (CFTR) dominates the Global CF market

Cystic fibrosis therapeutics include several medications, medical devices, and surgeries that help to reduce the progression of CF. The transmembrane conductance regulator (CFTR) protein is a chloride channel in the body that helps regulation of chlorine and sodium in and out of the cell membranes in the lungs and other organs. CFTR modulators help reduce lung flare-ups and respiratory symptoms by improving body function at the cellular level and enhancing patients' quality of life.

CFTR drugs hold the largest share in the market and are anticipated to witness significant growth over the forecast period. Furthermore, other advanced therapies, such as triple combination drugs, including CFTR modulators, will fuel industry growth.

Bronchodilator drugs are likely to witness the fastest CAGR growth across other drug classes. These are mostly used in patients suffering from respiratory disease and obstructive lung disorders. Other categories of drugs, such as Mucolytics, Pancreatic enzyme supplements, antibiotics, and anti-inflammatory among others, are used in patients with the disease to improve airway clearance or treat gastrointestinal disorders in patients suffering from the disease.

Oral drugs contribute the highest to the Global CF market

Oral drug formulations hold the largest share in the global cystic fibrosis market owing to the ease and convenience associated with taking the drugs orally. However, with the advent of new drug formulations which can be administered easily without the risk of invasive procedures, oral formulations may lose their market share to other formulation types such as inhalation drugs.

The growing usage of noninvasive medical interventions such as injections and inhalations will witness the highest CAGR growth owing to the preference for these options by medical practitioners. Additionally, inhaled drugs can be very well administered in high-risk patient groups that include cystic fibrosis patients suffering from respiratory disorders.

Hospital segment is leading the distribution channel analysis

The hospital segment registered the highest revenue share in 2021. The segmental growth is attributed to the growing prevalence of the disease and the need for accurate diagnosis and follow-up treatments under medical supervision. This leads to an increase in patient hospital visits propelling the hospital segment growth.

Furthermore, the high revenue contribution from hospital pharmacies is owing to the rising number of patient visits to the hospital for appointments and follow-ups. The increasing partnership of medical practitioners and healthcare centers with the hospital also accelerates the influx of patient admission to the hospitals. Such factors will increase the hospital's segment revenue and overall industry growth.

Growing prevalence of cystic fibrosis in North America will fuel CF market growth

North American region captures lucrative market share in 2022 and is poised to grow substantially over the coming years. The highest regional contribution is attributed to the increasing incidence of cystic fibrosis and the availability of multiple treatment options in the region.

Increasing funding for R&D projects on cystic fibrosis drugs and other favorable government initiatives will drive regional market growth. North American Cystic Fibrosis Conference (NACFC) has started offering educational forums to the cystic fibrosis community, enabling them to share the latest developments in the R&D space. Other factors, such as advanced healthcare infrastructure, presence of major market players, and reimbursements, are expected to propel the market growth.

In October 2019, the U.S. FDA approved a new triple combination therapy, i.e., Trikafta, to treat cystic fibrosis patients. This novel therapy will boost the survival possibilities of Cystic Fibrosis patients. Along with that, in August 2021, Cystic Fibrosis Canada insisted on standardized adoption guidelines for patient access to Trikafta with an aim to improve patients' quality of life and accelerate the adoption rate of the treatment procedure. 

Other regions and emerging countries have witnessed a growing awareness of the usage of oral drug treatments such as CFTR modulators and pancreatic enzyme supplements for the treatment of the disease, and their cost affordability is expected to drive regional cystic fibrosis market growth.

Competitive Insight

Major industry participants operating in the cystic fibrosis market include Vertex Pharmaceutical Incorporated, Teva Pharmaceuticals, AbbVie, Viatris Inc., Genentech Inc, Novartis AG, Mylan N.V, Pfizer Inc, BayerAG, Astrazeneca, Gilead Sciences, Nestle Health Science, Chiesi Farmacrutici, Roche, Pharmaxis Ltd., and Horizon Therapeutic Plc., among others.

Leading market participants are implementing various growth strategies to sustain industry competition in the market. New product launches supported by accelerated approvals will further propel the market growth. For instance, Vertex Pharmaceutical received U.S.FDA clearance for oral drug medications such as symdeko, orkambi, and ivacaftor in June 2019.

Recent Developments

  • March 2018, U.S. FDA approved the Vertex Pharmaceutical drug Symdeko. It was a combinational drug for the treatment of the disease and contained Ivacaftor and Tezacaftor.
  • October 2019, AbbVie and Cystic Fibrosis Foundation (CFF) formed a strategic alliance for the development of CFTR molecule. Partnership is bound to increase the product offerings in the market.
  • October 2020, Roche and Abbvie announced the partnership and acquired the TMEM 16A product portfolio. It is used in cystic fibrosis with a rare type of CFTR genotype and concerned respiratory illnesses. It helped firm to boost their product of offerings.

Cystic Fibrosis Market Report Scope

Report Attributes


Market size value in 2021

USD 5.75 billion

Revenue forecast in 2030

USD 37.04 billion


24.3 % from 2022 - 2030

Base year


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Segments covered

By Drug Class, By Route of Administration, By Distribution Channel, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Vertex Pharmaceutical Incorporated, Roche, Nestle Health Science, AbbVie, Viatris Inc., Horizon Therapeutic Plc., Novartis AG, Mylan N.V, Pfizer Inc, BayerAG, Astrazeneca, Genentech Inc, Gilead Sciences, Chiesi Farmacrutici, Pharmaxis Ltd., and Teva Pharmaceuticals

Seeking a more personalized report that meets your specific business needs? At Polaris Market Research, we’ll customize the research report for you. Our custom research will comprehensively cover business data and information you need to make strategic decisions and stay ahead of the curve.

Browse Our Top Selling Reports:

Molecular Quality Controls Market Size, Share 2024 Report

Animal Biotechnology Market Size, Share 2024 Report

Hemodialysis Market Size, Share 2024 Report

Recombinant Proteins Market Size, Share 2024 Report

Hormonal Contraceptive Market Size, Share 2024 Report